

Johnson & Johnson Innovative Medicine

Selected Novel Therapies - Recent Approvals/Potential Filings\*

(2023-2030 Key Filings, As Outlined at 2023 Enterprise Business Review)

Selective Highlights as of January 21, 2026

Assets with \$5B+ PYS Potential

- Oncology
- CD20-based CAR-T

Lymphoma
- ✓

RYBREVANT / LAZCLUZE

Non Small Cell Lung Cancer
- ✓

TALVEY (talquetamab)

Relapsed Refractory Multiple myeloma
- ✓

TARIS Platform \*

Bladder Cancer

- Immunology
- ☑

icotrokinra

Autoimmune Diseases
- Neuroscience
- ✓

IMAAVY (nipocalimab)

Autoantibody Diseases
- Select Other Areas
- Milvexian

Thrombosis

Assets with \$1 – 5B PYS Potential

- Oncology
- bleximenib

Hematologic Malignancies
- JNJ-5322 (BCMA/GPRC5D/CD3)

Hematologic Malignancies
- JNJ-6420 225Ac KLK2

Prostate Cancer
- JNJ-8343 KLK2 / CD3

Prostate Cancer
- JNJ-8543 (CD79/CD20/CD3)

Hematologic Malignancies
- ✓

AKEEGA (niraparib/abiraterone)

Metastatic castration-resistant prostate cancer (mCRPC)
- Immunology
- JNJ-4804 Co-antibody Therapy

Inflammatory Bowel Disease
- Neuroscience
- JNJ-1887 sCD59

Geographic Atrophy
- RPGR Gene Therapy

Retinitis Pigmentosa
- seltorexant

Adjunctive treatment for major depressive disorder with insomnia symptoms

- ☑

Submitted in US or EU
- ✓

Approved in US or EU

PYS refers to peak year non-risk adjusted operational sales, including partner sales. Filings/approvals assumed to be in the US and EU unless otherwise noted. This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of the date hereof to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information.

Niraparib licensed from Tesaro; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab); Lazertinib licensed from Yuhan Corporation; AAV-RPGR licensed from UCL Business Plc; JNJ-1887 acquired from Hemera Biosciences; Milvexian co-developed with Bristol Myers Squibb; (CAR) T-cell therapies [JNJ-90014496 and JNJ-90009530] AbelZeta collaboration and license agreement; JNJ-2113 licensed from and co-developing with Protagonist Therapeutics, Inc.; NBTXR3: Nanobiotix

\*Total TARIS platform is expected to be \$5B+ in non risk adjusted peak year sales. This includes both TAR-200 and TAR-210; approval above is specific to only TAR-200.